

Short Note

2-(5-Acetyl-7-methoxy-2-(4-methoxyphenyl)benzofuran-3-yl)acetic Acid

Boris V. Lichitsky, Andrey N. Komogortsev *  and Valeriya G. Melekhina

N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Science, Leninsky Pr., 47,
119991 Moscow, Russia; blich2006@mail.ru (B.V.L.); melekhinavg@gmail.com (V.G.M.)

* Correspondence: dna5@mail.ru

Abstract: We elaborated a convenient one-step approach for the synthesis of previously unknown 2-(5-acetyl-7-methoxy-2-(4-methoxyphenyl)benzofuran-3-yl)acetic acid. The suggested protocol includes the multicomponent reaction of acetovanillone, 4-methoxyphenylglyoxal and Meldrum's acid. We have demonstrated that the considered reaction is a one-pot telescoped process including the preliminary condensation of the components in MeCN followed by acid-catalyzed cyclization. The structure of the synthesized product was confirmed by ^1H , ^{13}C -NMR spectroscopy and high-resolution mass-spectrometry.

Keywords: acetovanillone; arylglyoxal; meldrum's acid; multicomponent reaction



Citation: Lichitsky, B.V.; Komogortsev, A.N.; Melekhina, V.G. 2-(5-Acetyl-7-methoxy-2-(4-methoxyphenyl)benzofuran-3-yl)acetic Acid. *Molbank* **2022**, *2022*, M1357. <https://doi.org/10.3390/M1357>

Academic Editor: Nicholas
E. Leadbeater

Received: 17 March 2022

Accepted: 24 March 2022

Published: 1 April 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction


Acetovanillone (Apocynin) is a natural organic compound structurally related to vanillin found in plant sources [1,2]. Acetovanillone has a wide spectrum of biological activity. For example, apocynin can influence the immune system through the inhibition of NADPH oxidase [3–11]. Besides that, acetovanillone is used as an anti-arthritic [12,13] and anti-asthmatic agent [14]. Additionally, apocynin can be employed for the treatment of bowel diseases [15] and atherosclerosis [16]. Finally, it was shown that this compound displays significant activity against amyotrophic lateral sclerosis [17]. In this regard, the preparation of synthetic derivatives of acetovanillone, which may also have various biological activities, is of considerable interest.

Previously, we proposed a general method for the preparation of condensed furylacetic acids based on a multicomponent reaction of hydroxyl derivatives with arylglyoxals and Meldrum's acid [18–24]. It should be noted that the considered method allows one to synthesize the wide range of furylacetic acids from the diverse phenols. We assumed that the presented approach could be applied to obtain the condensed acetovanillone derivatives.

2. Results and Discussion


In the present paper, we describe a multicomponent reaction of acetovanillone **1**, 4-methoxyphenylglyoxal **2** and Meldrum's acid **3** leading to 2-(5-acetyl-7-methoxy-2-(4-methoxyphenyl)benzofuran-3-yl)acetic acid **4** unknown in the literature (Scheme 1). It was shown that the studied reaction was a one-pot telescoped two stage process. The first step involves the condensation of the starting components in acetonitrile in the presence of triethylamine. Note that the initial stage of the process can be carried out under mild conditions at room temperature due to the high solubility of acetovanillone **1**. In this case, the reaction proceeds rather slowly, and a complete conversion of apocynin **1** was observed in 48 h. At the same time, our attempts to accelerate the process by increasing the temperature of the first stage led to a significant decrease in the yield of the target product **4**. It should be mentioned that the final step of the reaction involves intramolecular cyclization in a mixture of hydrochloric and acetic acids. As was shown previously, these conditions

are optimal for the last stage of the process [18–24]. Thus, the presented approach allows one to obtain the target product **4** in a 62% yield.



Scheme 1. Synthesis of 2-(5-acetyl-7-methoxy-2-(4-methoxyphenyl)benzofuran-3-yl)acetic acid **4**.

The assumed pathway of the considered reaction is shown in Scheme 2. At first, the condensation of 4-methoxyphenylglyoxal **2** with Meldrum's acid **3** results in unstable Michael acceptor **A**. Then, the interaction of acetovanillone anion **B** with aroylmethylene derivative **A** leads to adduct **D**. At the next step, intermediate **D** cyclizes into γ -ketoacid **F** with the elimination of acetone and CO_2 molecules. Finally, the target furylacetic acid **4** is formed as a result of an acid-catalyzed intramolecular cyclization of compound **F**.



Scheme 2. The assumed reaction pathway for the formation of compound **4**.

The synthesized 2-(5-acetyl-7-methoxy-2-(4-methoxyphenyl)benzofuran-3-yl)acetic acid **4** is the solid crystalline compound, whose structure was confirmed by ^1H , ^{13}C NMR spectroscopy and high-resolution mass-spectrometry. ^1H NMR spectra of the product **4** contain characteristic signals of the protons of the carboxymethylene fragment in the region δ 3.89 ppm and 12.57 ppm. The remaining signals are also in good agreement with the presented structure.

In summary, we suggested an efficient method for the modification of naturally occurring acetovanillone. The considered approach allows one to synthesize the previously unknown 2-(5-acetyl-7-methoxy-2-(4-methoxyphenyl)benzofuran-3-yl)acetic acid. The studied reaction is based on the multicomponent condensation of acetovanillone, 4-methoxyphenylglyoxal and Meldrum's acid. The advantages of this protocol are the application of readily available starting compounds, an atom economy and an easy work-up

procedure, which can avoid chromatographic purification. The structure of the synthesized product was confirmed by ^1H , ^{13}C -NMR spectroscopy and high-resolution mass-spectrometry.

3. Materials and Methods

All starting chemicals and solvents were commercially available and were used as received. NMR spectra were recorded with Bruker DRX 300 (300 MHz) spectrometers (Billerica, MA, USA) in $\text{DMSO-}d_6$. Chemical shifts (ppm) were given relative to solvent signals ($\text{DMSO-}d_6$: 2.50 ppm (^1H NMR) and 39.52 ppm (^{13}C NMR)). High-resolution mass spectra (HRMS) were obtained on a Bruker micrOTOF II instrument (Bruker Daltonik GmbH, Bremen, Germany) using electrospray ionization (ESI). The melting points were determined on a Kofler hot stage (Dresden, Germany). IR spectra were recorded on a Bruker ALPHA (Santa Barbara, CA, USA) spectrophotometer in a KBr pellet.

Experimental Procedure for the Synthesis of 2-(5-Acetyl-7-methoxy-2-(4-methoxyphenyl)benzofuran-3-yl)acetic Acid 4

A mixture of acetovanillone **1** (3 mmol, 0.5 g), 4-methoxyphenylglyoxal hydrate **2** (5 mmol, 0.91 g), Meldrum's acid **3** (6 mmol, 0.86 g), and Et_3N (7 mmol, 1 mL) in 6 mL of MeCN was kept for 48 h at room temperature. Then, 2 mL AcOH was added, and the reaction mixture was evaporated in *vacuo*. 3 mL of conc. HCl and 5 mL of AcOH were added to the residue, and the solution was refluxed for 15 min. The resulting mixture was stirred for 2 h at room temperature and left overnight. The formed precipitate was collected by filtration and washed with 50% aqueous AcOH (3×7 mL). To remove traces of HCl and AcOH, the precipitate was kept for 24 h in water (50 mL) at room temperature, collected by filtration, and washed with water (3×10 mL). Beige powder; yield 62% (0.66 g, 1.9 mmol); mp 193–195 °C. ^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ 12.57 (br.s, 1H), 7.96 (s, 1H), 7.72 (d, $J = 8.8$ Hz, 2H), 7.45 (s, 1H), 7.12 (d, $J = 8.7$ Hz, 2H), 4.02 (s, 3H), 3.89 (s, 2H), 3.83 (s, 3H), 2.64 (s, 3H). ^{13}C NMR (75 MHz, $\text{DMSO-}d_6$) δ 197.25, 171.84, 159.93, 153.25, 144.77, 144.59, 133.36, 131.57, 128.26, 121.85, 114.59, 114.18, 109.34, 106.01, 55.99, 55.33, 29.94, 26.79. IR spectrum (KBr), ν , cm^{-1} : 3418, 3089, 3056, 3000, 2980, 2945, 2841, 2706, 2596, 2361, 2341, 2042, 1852, 1720, 1646, 1615, 1589, 1512, 1481, 1466, 1422, 1391, 1321, 1302, 1260, 1218, 1178, 1088, 1053, 1026. HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $\text{C}_{20}\text{H}_{18}\text{O}_6$ 355.1176; Found 355.1173.

Supplementary Materials: The following are available online: copies of ^1H , ^{13}C -NMR, mass and IR spectra for compound **4**. Figure S1: ^1H NMR spectrum (300 MHz) of compound **4** in $\text{DMSO-}d_6$; Figure S2: ^{13}C (^1H) NMR spectrum (75 MHz) of compound **4** in $\text{DMSO-}d_6$; Figure S3: HRMS for compound **4**; Figure S4: IR spectrum for compound **4**.

Author Contributions: A.N.K.—conceptualization, synthesis, spectroscopic analysis and writing the manuscript. B.V.L.—conceptualization, synthesis, spectroscopic analysis and writing the manuscript. V.G.M.—conceptualization, synthesis, spectroscopic analysis and writing the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data for the compounds presented in this study are available in the Supplementary Materials of this article.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Debnath, P.; Rathore, S.; Walia, S.; Kumar, M.; Devi, R.; Kumar, R. Picrorhiza Kurroa: A Promising Traditional Therapeutic Herb from Higher Altitude of Western Himalayas. *J. Herb. Med.* **2020**, *23*, 100358. [[CrossRef](#)]
2. Kumar, S.; Patial, V.; Soni, S.; Sharma, S.; Pratap, K.; Kumar, D.; Padwad, Y. Picrorhiza Kurroa Enhances β -Cell Mass Proliferation and Insulin Secretion in Streptozotocin Evoked β -Cell Damage in Rats. *Front. Pharmacol.* **2017**, *8*, 537. [[CrossRef](#)] [[PubMed](#)]

3. Yang, T.; Zang, D.-W.; Shan, W.; Guo, A.-C.; Wu, J.-P.; Wang, Y.-J.; Wang, Q. Synthesis and Evaluations of Novel Apocynin Derivatives as Anti-Glioma Agents. *Front. Pharmacol.* **2019**, *10*, 951. [[CrossRef](#)] [[PubMed](#)]
4. Petrônio, M.; Zeraik, M.; Fonseca, L.; Ximenes, V. Apocynin: Chemical and Biophysical Properties of a NADPH Oxidase Inhibitor. *Molecules* **2013**, *18*, 2821–2839. [[CrossRef](#)]
5. Stefanska, J.; Pawliczak, R. Apocynin: Molecular Aptitudes. *Mediat. Inflamm.* **2008**, *2008*, 106507. [[CrossRef](#)] [[PubMed](#)]
6. Cross, A.L.; Hawkes, J.; Wright, H.L.; Moots, R.J.; Edwards, S.W. APPA (Apocynin and Paeonol) Modulates Pathological Aspects of Human Neutrophil Function, without Suppressing Antimicrobial Ability, and Inhibits TNF α Expression and Signalling. *Inflammopharmacology* **2020**, *28*, 1223–1235. [[CrossRef](#)] [[PubMed](#)]
7. Montes-Rivera, J.O.; Tamay-Cach, F.; Quintana-Pérez, J.C.; Guevara-Salazar, J.A.; Trujillo-Ferrara, J.G.; Del Valle-Mondragón, L.; Arellano-Mendoza, M.G. Apocynin Combined with Drugs as Adjuvant Could Be Employed to Prevent and/or Treat the Chronic Kidney Disease. *Ren. Fail.* **2018**, *40*, 92–98. [[CrossRef](#)]
8. Boshtam, M.; Kouhpayeh, S.; Amini, F.; Azizi, Y.; Najafu, M.; Shariati, L.; Khanahmad, H. Anti-Inflammatory Effects of Apocynin: A Narrative Review of the Evidence. *Life* **2021**, *14*, 997–1010. [[CrossRef](#)]
9. Abdelmageed, M.E.; El-Awady, M.S.; Suddek, G.M. Apocynin Ameliorates Endotoxin-Induced Acute Lung Injury in Rats. *Int. Immunopharmacol.* **2016**, *30*, 163–170. [[CrossRef](#)]
10. Wang, K.; Li, L.; Song, Y.; Ye, X.; Fu, S.; Jiang, J.; Li, S. Improvement of Pharmacokinetics Behavior of Apocynin by Nitron Derivatization: Comparative Pharmacokinetics of Nitron-Apocynin and Its Parent Apocynin in Rats. *PLoS ONE* **2013**, *8*, e70189. [[CrossRef](#)]
11. Choi, S.H.; Suh, G.J.; Kwon, W.Y.; Kim, K.S.; Park, M.J.; Kim, T.; Ko, J.I. Apocynin Suppressed the Nuclear Factor-KB Pathway and Attenuated Lung Injury in a Rat Hemorrhagic Shock Model. *J. Trauma Acute Care Surg.* **2017**, *82*, 566–574. [[CrossRef](#)] [[PubMed](#)]
12. 'T Hart, B.A.; Simons, J.M.; Shoshan, K.-S.; Bakker, N.P.M.; Labadie, R.P. Antiarthritic Activity of the Newly Developed Neutrophil Oxidative Burst Antagonist Apocynin. *Free Radic. Biol. Med.* **1990**, *9*, 127–131. [[CrossRef](#)]
13. 'T Hart, B.A.; Copray, S.; Philippens, I. Apocynin, a Low Molecular Oral Treatment for Neurodegenerative Disease. *BioMed Res. Int.* **2014**, *2014*, 298020. [[CrossRef](#)] [[PubMed](#)]
14. Van den Worm, E.; Beukelman, C.J.; Van den Berg, A.J.J.; Kroes, B.H.; Labadie, R.P.; Van Dijk, H. Effects of Methoxylation of Apocynin and Analogs on the Inhibition of Reactive Oxygen Species Production by Stimulated Human Neutrophils. *Eur. J. Pharmacol.* **2001**, *433*, 225–230. [[CrossRef](#)]
15. Palmen, M.; Beukelman, C.; Mooij, R.; Pena, A.; Vonrees, E. Anti-Inflammatory Effect of Apocynin, a Plant-Derived NADPH Oxidase Antagonist, in Acute Experimental Colitis. *Neth. J. Med.* **1995**, *47*, A41. [[CrossRef](#)]
16. Pandey, A.; Kour, K.; Bani, S.; Suri, K.A.; Satti, N.K.; Sharma, P.; Qazi, G.N. Amelioration of Adjuvant Induced Arthritis by Apocynin: Amelioration of adjuvant induced arthritis by apocynin. *Phytother. Res.* **2009**, *23*, 1462–1468. [[CrossRef](#)] [[PubMed](#)]
17. Harraz, M.M.; Marden, J.J.; Zhou, W.; Zhang, Y.; Williams, A.; Sharov, V.S.; Nelson, K.; Luo, M.; Paulson, H.; Schöneich, C.; et al. SOD1 Mutations Disrupt Redox-Sensitive Rac Regulation of NADPH Oxidase in a Familial ALS Model. *J. Clin. Invest.* **2008**, *118*, JCI34060. [[CrossRef](#)]
18. Komogortsev, A.N.; Lichitsky, B.V.; Melekhina, V.G. Straightforward One-Step Approach towards Novel Derivatives of 9-Oxo-5,6,7,9-Tetrahydrobenzo[9,10]Heptaleno[3,2-b]Furan-12-Yl)Acetic Acid Based on the Multicomponent Reaction of Colchicine, Arylglyoxals and Meldrum's Acid. *Tetrahedron Lett.* **2021**, *78*, 153292. [[CrossRef](#)]
19. Gorbunov, Y.O.; Lichitsky, B.V.; Komogortsev, A.N.; Mityanov, V.S.; Dudinov, A.A.; Krayushkin, M.M. Synthesis of Condensed Furylacetic Acids Based on Multicomponent Condensation of Heterocyclic Enols with Arylglyoxals and Meldrum's Acid. *Chem. Heterocycl. Compd.* **2018**, *54*, 692–695. [[CrossRef](#)]
20. Komogortsev, A.N.; Lichitsky, B.V.; Tretyakov, A.D.; Dudinov, A.A.; Krayushkin, M.M. Investigation of the Multicomponent Reaction of 5-Hydroxy-2-Methyl-4H-Pyran-4-One with Carbonyl Compounds and Meldrum's Acid. *Chem. Heterocycl. Compd.* **2019**, *55*, 818–822. [[CrossRef](#)]
21. Lichitsky, B.V.; Melekhina, V.G.; Komogortsev, A.N.; Minyaev, M.E. A New Multicomponent Approach to the Synthesis of Substituted Furan-2(5H)-Ones Containing 4H-Chromen-4-One Fragment. *Tetrahedron Lett.* **2020**, *61*, 152602. [[CrossRef](#)]
22. Lichitsky, B.V.; Tretyakov, A.D.; Komogortsev, A.N.; Mityanov, V.S.; Dudinov, A.A.; Gorbunov, Y.O.; Daeva, E.D.; Krayushkin, M.M. Synthesis of Substituted Benzofuran-3-Ylacetic Acids Based on Three-Component Condensation of Polyalkoxyphenols, Arylglyoxals and Meldrum's Acid. *Mendeleev Commun.* **2019**, *29*, 587–588. [[CrossRef](#)]
23. Lichitsky, B.V.; Komogortsev, A.N.; Melekhina, V.G. 2-(2-(4-Methoxyphenyl)Furo[3,2-*h*]Quinolin-3-Yl)Acetic Acid. *Molbank* **2022**, *2022*, M1315. [[CrossRef](#)]
24. Lichitsky, B.V.; Komogortsev, A.N.; Melekhina, V.G. 2-(2-(4-Methoxyphenyl)-4,9-Dimethyl-7-Oxo-7H-Furo[2,3-*f*]Chromen-3-Yl)Acetic Acid. *Molbank* **2021**, *2021*, M1304. [[CrossRef](#)]